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Abstract
Purpose The biokinetics and dosimetry of 111In-DOTA-
NOC-ATE (NOCATE), a high-affinity ligand of SSTR-2
and SSTR-5, and 111In-DTPA-octreotide (Octreoscan™,
OCTREO) were compared in the same patients.
Methods Seventeen patients (10 men, 7 women; mean age
60 years), referred for an OCTREO scan for imaging of a
neuroendocrine tumour (15), thymoma (1) or medullary
thyroid carcinoma (1), agreed to undergo a second study
with NOCATE. Whole-body anterior–posterior scans were
recorded 0.5 (100 % reference scan), 4, 24 and 48 h (17
patients) and 120 h (5 patients) after injection. In 16 patients
the OCTREO scan (178±15 MBq) was performed 16±
5 days before the NOCATE scan (108±14 MBq) with
identical timing; 1 patient had the NOCATE scan before
the OCTREO scan. Blood samples were obtained from 14
patients 5 min to 48 h after injection. Activities expressed as
percent of the initial (reference) activity in the whole body,
lung, kidney, liver, spleen and blood were fitted to biexpo-
nential or single exponential functions. Dosimetry was per-
formed using OLINDA/EXM.
Results Initial whole-body, lung and kidney activities were
similar, but retention of NOCATE was higher than that of
OCTREO. Liver and spleen uptakes of NOCATE were
higher from the start (p<0.001) and remained so over time.
Whole-body activity showed similar α and β half-lives, but
the β fraction of NOCATE was double that of OCTREO.
Blood T1/2β for NOCATE was longer (19 vs. 6 h). As a
result, the effective dose of NOCATE (105 μSv/MBq)
exceeded that of OCTREO (52 μSv/MBq), and the latter
result was similar to the ICRP 106 value of 54 μSv/MBq.
Differential activity measurement in blood cells and plasma
showed an average of <5 % of NOCATE and OCTREO
attached to globular blood components.
Conclusion NOCATE showed a slower clearance from nor-
mal tissues and its effective dose was roughly double that of
OCTREO.
Keywords 111In-DOTA-NOC-ATE . 111In-DTPA-
octreotide . Biokinetics . Dosimetry . Neuroendocrine
tumours . Somatostatin receptor
Introduction
The somatostatin receptor (SSTR), identified by Reubi et al.
[1], can be expressed as five different subtype forms (SSTR
1 to 5) [2]. 111In-labelled DTPA-octreotide (Octreoscan™;
referred to here as OCTREO) binds with high and moderate
affinity to SSTR 2 and 5 (IC50 2 and 22 nmol/l, respective-
ly), and with low affinity to SSTR 3 (IC50 187 nmol/l) [3].
SSTR 2 is expressed in most neuroendocrine tumours, but
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may occasionally be absent while other SSTR subtypes can
be present [4]. New analogues of somatostatin including
DOTA-NOC-ATE have been described [5]. 111In-DOTA-
NOC-ATE binds with high affinity to SSTR subtypes 2
and 5 (IC50 2 and 4.3 nmol/l, respectively), with moderate
affinity to SSTR 3 (IC50 13 nmol/l) and with low affinity to
SSTR 4 (IC50 160 nmol/l) [3] (Fig. 1). In the present study,
the biodistribution and dosimetry of NOCATE were pro-
spectively studied in comparison with those of OCTREO.
DOTA-conjugated reagents have the advantage of strongly
chelating radiometals. Such reagents include the γ and posi-
tron emitters 111In and 68Ga and therapeutic β− radiation
emitters of high energy (90Y) and intermediate energy
(177Lu). In this prospective comparative study, we decided to
use 111In-labelled NOCATE and OCTREO to take advantage
of the identical scintigraphic qualities of the two reagents.
The relevance for scintigraphy and for therapy of the
affinity towards particular SSTRs is not known. However,
It is reasonable to assume that the log difference in affinity
for receptor subtypes of NOCATE compared with OCTREO
could play a role in its uptake in tumour and normal tissues
that express these subtypes.
The aim of this study was therefore to evaluate whether
the higher affinity of NOCATE for SSTRs 3 and 5 compared
with OCTREO influences the biodistribution and bioki-
netics in patients with neuroendocrine tumours. With this
perspective, we compared the two 111In-labelled radiophar-
maceuticals in patients referred for diagnostic imaging with
OCTREO. In a subgroup of 14 patients, blood samples were
taken at the time of imaging. Here we present the first head-
to-head comparison of the biokinetics and dosimetry of
NOCATE with OCTREO. Evaluation of tumour imaging
with the two reagents will be reported separately.
Patients and methods
This prospective, comparative study was authorized by
the local Ethics Committees of the Lausanne and
Geneva University Hospitals, by Swissmedic and the
Swiss Federal Office of Public Health (OFSP), Section
of Radioprotection, and was performed in accordance
with the ethical standards laid down in the 1964
Declaration of Helsinki. All patients gave their written
informed consent to participate in the study.
Patients with a diagnosis of a tumour expected to express
SSTRwhowere referred for anOCTREO scanwere invited to
participate in the study provided they were aged ≥18 years,
capable of providing informed consent and had a Karnofsky
index of ≥60 %. Exclusion criteria were the presence of
any severe infection, bone marrow insufficiency with
leucocytes <2,500/μl or platelets <100,000/μl, liver or kidney
disease with transaminases (AST/ALT), bilirubin or creatinine
more than twice the upper limits of normal, and participation
in another study. Pregnant and breastfeeding women were
excluded, and all participants had to agree to 3 months of
contraception after the first clinical study with NOCATE. Of
the 17 patients, 15 had a neuroendocrine tumour, and 1 each
had a thymoma and a medullary thyroid carcinoma. Four
patients had no detectable tumour at the time of the study.
OCTREO
Labelling and administration of OCTREO (10 μg, 178±
15 MBq per patient; the formulation containing trisodium
citrate, citric acid and inositol as well gentisic acid) and
scintigraphy were performed according to the manufac-
turer’s (Mallinckrodt, Maryland Heights, MO) instructions.
Planar whole-body (WB) scintigraphy was performed at
0.5 h without bladder voiding (100 % reference scan) and
at 4, 24 and 48 h (empty bladder) after injection. Five
patients agreed to have an additional scan at 120 h after
injection of OCTREO and after injection of NOCATE.
Scanning was performed on a dual-head gamma camera
(Biad; Trionix Research Laboratory, Twinsburg, OH) in a
256×1,024 matrix, using a medium energy collimator and
narrow energy windows of 171±15 % and 245±15 %keV
with the detector heads at a stable distance. A standard
containing 1.8 MBq 111In in 10 ml prepared at the time of
the first scan was scanned at each time point and in the
identical position immediately before the patient was
scanned.
NOCATE
The NOCATE precursor was prepared in a documented,
controlled manner. The final analysis, including controls of
organic and inorganic solvents and an acute toxicity study,
were evaluated at independent institutions. Toxicity at a
dose of 1.5 mg/kg (5,000-fold patient dose) was tested in
six female HanLbm NMRI mice (SPF) according to OECD
Guidelines for the Testing of Chemicals no. 432 and
Fig. 1 Affinity profiles of OCTREO and NOCATE as reported previ-
ously [5]. Affinities from high to low (IC50 values from low to high):
thick arrows, medium arrow, thin arrows, broken arrows (IC50>
100 nmol/L). The IC50 values of OCTREO for SSTRs 2, 5 and 3 are
2±0.7, 22±6 and 187±55 nmol/L (mean ± SE), respectively. The IC50
values of 111In-NOCATE for SSTRs 2, 5, 3 and 4 are 2±0.6, 4.3±0.5,
13±4 and 160±3.8 nmol/L (mean ± SE), respectively [5]
Eur J Nucl Med Mol Imaging (2012) 39:1868–1875 1869
Directive 96/54/EEC, B.1 trials. The animal study (RCC
study no. 849627) was performed in an AAALAC-
approved laboratory in accordance with Swiss Animal
Protection laws under license no. 82 at RRC Ltd.,
Füllinsdorf, Switzerland. NOCATE at the controlled level
was shown to be not toxic.
NOCATE (20 μg in 50 μl aqueous solution) was radio-
labelled with 111 MBq 111In in 0.3-ml aqueous solution.
111In was buffered with 40 μl sodium acetate 0.3 M (pH 4.5
to 5), mixed with the peptide and incubated for 0.5 h at
100 °C. The labelling solution was buffered with 0.11 ml
0.573 M Na2HPO4 and 5 ml physiological NaCl solution
was added. After filtration through a Millipore 0.2-μm
sterile filter, the final patient solution was ready for use,
provided the radiochemical purity of ≥95 % had been
reached. Under these conditions with kit formulations and
peptide in solution (20 μg), the desired injection activity of
NOCATE was obtained at a radiochemical purity of >95 %
in all patients.
NOCATE was administered after a planned delay of
2 weeks from the OCTREO scan, except in one patient
who had the NOCATE scan first followed with the same
delay by the OCTREO scan. No particular difference in
biodistribution compared with the other patients was
observed in this latter patient whose data were therefore
handled in the same manner as those of all other
patients. After intravenous injection of 108±14 MBq 111In-
NOCATE, scintigraphy was performed at 0.5, 4, 24 and 48 h
and in five patients also at 120 h after injection. Again, a
standard sample of 1.8 MBq 111In (prepared at the time of the
initial NOCATE scan) was scanned immediately before the
patients. In all individual patients, the number and time-points
of the NOCATE and OCTREO scans and for the blood
sampling were identical.
Biodistribution
Regions of interest were drawn contouring the whole
body and organs on the anterior and posterior views.
After background correction and calculating the geomet-
ric mean, activity was expressed as percent of total
body activity of the scan obtained 30 min after injection
representing the injected activity. Regarding the lungs,
contouring was performed so as to minimize mediastinal
scatter. Kidney background correction was performed by
defining the activity in an external circular crescent
from the upper to lower poles of the kidney and cor-
recting the activity of the renal surface with respect to
that of the crescent. We estimated that the underlying
liver activity on the right kidney was adequately sub-
tracted in this way. In most patients liver metastases
were not observed and when they were occasionally
seen, the background correction would, in our opinion,
have adequately dealt with them. Corrected kidney up-
take was measured on posterior images only and
expressed as percent of the posterior WB scan.
Attenuation and scatter correction were not performed
in this study.
Activities at different scan times were corrected for
the physical half-life of 111In. WB, lung, liver, spleen,
kidney and bladder activities as well as activities in the
remainder of the body are expressed as percent of
injected activity (initial WB scan) in all patients. The
activity of the standard sample (prepared at the time of
the first scan) was measured, and corrected for back-
ground and decay to evaluate the stability of the scan-
ner and procedure.
Blood sampling
Blood samples were taken at 5, 15, 30 and 60 min and at 4,
24 and 48 h after injection in 14 patients (9 men, 5 women).
In 5 patients blood samples were also taken at 120 h. The
activity of 1-ml aliquots from all collected blood samples
was counted on the last study day, 48 or 120 h after injec-
tion. In seven patients activity was analysed separately for
the globular fraction and plasma and the haematocrit value
of each patient was used to determine the respective
volumes.
Half-lives of organs, total body, remainder of body
and blood activities
WB, lung, liver and blood activities were fitted to
biexponential functions for male and female patients
and then also for all patients together using UNISTAT
5.6 statistical package for Windows (Unistat, London).
The results of the biexponential function fittings are
given as means ± standard error. Kidney and spleen
activities fitted best to single exponential functions that
were performed on Excel in all patients individually.
Results of the single exponential functions are given
as means ± 1 SD.
Dosimetry
OLINDA (OLINDA/EXM 1.0; Vanderbilt University) was
used to calculate organ and tissue radiation doses from
OCTREO and NOCATE [6]. According to the published
method, red marrow residence time was extrapolated from
the blood residence time assuming identical extracellular
activity concentrations and half-lives and setting the blood
to marrow residence time ratio to 0.091 [7]. The urinary
bladder model [6] was used to evaluate the residence time
for bladder. We assumed for OCTREO (in accordance with
ICRP guidelines) and NOCATE that all activity was
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eliminated via the kidneys in the urine. Accordingly the
parameter for the kidney elimination fraction was set to 1.
The fractions (f) of the biological α and β WB half-lives in
patients were introduced into the bladder model and both
residence times were summed. The bladder voiding interval
used was 2 h. The summed residence times for the bladder
of OCTREO and NOCATE were introduced into the
OLIDA dose calculations.
Statistical evaluation
Uptake in tissues was compared between NOCATE and
OCTREO using the paired Student’s t test. Values of p<
0.05 were considered significant and <0.001 as highly sig-
nificant. The uncertainty of the residence time, dτ, was
determined using the propagation of the uncertainties on
f1, T1/2,1, f2 and T1/2,2 (f1 and f2 are the prefactors for T1/2α
and T1/2β, respectively) obtained from the least-squares
fitting of the biexponential function, as follows [8]:
dt ¼ 1:44 
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Results
The patient characteristics are presented in Table 1. Injections
of OCTREO and NOCATEwere well tolerated by all patients.
Biodistribution of NOCATE and OCTREO
For the 111In standards, the differences between the counts
of the highest and lowest samples were <2 % in 117 scans
(86 %), ≤5 % in 13 scans (10 %) and 5–10 % in and 3 scans
(2 %). In the whole body the percent activity of NOCATE
was roughly twice that of OCTREO at 24, 48 and
120 h after injection (Table 2). In the lungs and
kidneys, the initial uptakes were similar between the
two compounds, but NOCATE showed a longer retention than
OCTREO (p<0.05 and <0.001; Table 2). In the liver and
spleen, however, the uptake of NOCATE was higher than that
of OCTREO from the start, the half-lives being rather similar
(Table 2). In four patients with a major metastatic load
(Table 2). the liver was not included in dosimetry. In men
and women, although their body weight differed markedly,
tissue uptakes, as shown in Table 2, overlapped with no major
trend for a difference between genders. All data are therefore
presented for the 17 patients combined. Images obtained in an
example patient comparing the biodistribution of NOCATE
and OCTREO 4 h after injection are shown in Fig. 2.
Residence times in organs, total body and blood
For dosimetry, the total body, liver, lungs and blood data
were fitted to biexponential functions (Figs. 3, 4 and 5,
respectively). The patients were initially divided for analysis
according to gender (ten men, seven women), but since the
results in these two subgroups were very similar for both
OCTREO and NOCATE (OCTREO in accordance with
ICRP [9]), the final analysis was performed for all patients
together. The measured uptakes in the spleen and kidneys
fitted best to single exponential functions that were calcu-
lated for each patient individually. For these two organs, the
curves (Fig. 4) showed the mean of all half-lives calculated
individually. For both genders, the extrapolated residence
times of NOCATE were roughly double those of OCTREO,
and thus are also given for all patients together (Table 3).
Blood activity of OCTREO (Fig. 5a) showed a high vari-
ability over the initial 24 h after injection with very low values
Table 1 Patient characteristics
Characteristic Value
Patients (N)
Women 7
Men 10
Age (years)
Median 61
Range 44–79
Weight (kg, mean ± SD)
Women 56±6
Men 82±11
Tumour diagnosis
Neuroendocrine tumour 15
Thymoma 1
Medullary thyroid carcinoma 1
OCTREO injected
Activity (MBq, mean ± SD, N017) 178±15
Amount (μg/patient) 10
NOCATE injected
Activity (MBq, mean ± SD, N017) 108±14
Amount (μg/patient) 20
Time between scans (days)
OCTREO to NOCATE (mean ± SD, N016) 16±5
NOCATE to OCTREO (N01) 14
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Fig. 2 WB scans (posterior and anterior views) at 4 h with OCTREO
(a) and NOCATE (b) in a patient who was tumour-free at the time of
scanning
Fig. 3 WB activity in all patients corrected for the physical half-life of
111In shown as percent of initial activity (reference scan) for OCTREO
(a) and NOCATE (b). A biexponential function of activity was fitted to
all combined values from individual patients shown for each scan time
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at 48 h and 120 h. In marked contrast, the NOCATE results
were within a narrow range (Fig. 5b) showing a rapid decrease
(α half-life) followed by a sharp transition into a long β half-
life. The resulting 95 % confidence interval for OCTREO was
thus larger than for NOCATE (Fig. 5). The summed blood α
andβ residence times (Table 3) of NOCATEwere again much
higher than those of OCTREO.
We checked whether a difference in cell-bound activity
could explain the difference in blood clearance of OCTREO
and NOCATE in seven patients (six men, one woman). For
each patient, seven or eight paired blood samples were avail-
able both for OCTREO and NOCATE. Based on the haema-
tocrit values, plasma activity was determined and compared
with the measured blood activity. The results showed
that 98.2±3.5 % of OCTREO activity was in the plasma while
for NOCATE the percentage was slightly, but significantly,
lower (96.8±4.1 %, p<0.05; results not shown).
Dosimetry of NOCATE and OCTREO
Dosimetry showed a consistently higher radiation dose from
NOCATE than from OCTREO, except in the bladder where
no increase was observed. For kidneys, the dose increase of
NOCATE compared with OCTREO was slightly less marked
than for other organs and the remainder of body (Table 4).
Comparison of the dosimetry of OCTREO in these
patients with the ICRP data [9] revealed a higher value for
the lungs. Overall, however, the calculated ED in our
patients of 52 μSv/MBq correlated quite well with the
ICRP value of 54 μSv/MBq.
Discussion
Despite a large difference in mean body weight between
men and women (82 kg for men and 56 kg for women), the
biodistributions of NOCATE and OCTREO (percentage of
Fig. 4 Organ and bladder activities in all patients corrected for the
physical half-life of 111In shown as percent of WB activity at the time
of the first scan (reference scan) for OCTREO (a) and NOCATE (b).
Patient values are shown as mean ± SD for each scan time. The mean
of the single exponential functions fitted to individual patient values
are shown for the kidneys and spleen. Biexponential functions of
activity were fitted to the combined patient values for the liver and
lungs
Fig. 5 Blood activity obtained in 14 patients expressed as percent of
initial measured activity (at 5 min, set to 100 %) shown for OCTREO
(a) and NOCATE (b). Biexponential functions fitted to the combined
patient values of all blood drawings at all times show the effective half-
lives. Broken lines indicate 95 % confidence intervals; symbols indicate
all individual patient values
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injected activity per organ, blood and whole body) were
very similar between the genders. Very similar residence
times were thus observed in male and female patients for
both NOCATE and OCTREO, and we therefore pooled the
results for the genders. Our observations regarding
OCTREO were in good agreement with the published
ICRP dosimetry data [9]. It is worthy of note that the
ICRP used identical residence times for men and women.
NOCATE also gave similar results in men and women,
further justifying the presentation of the results of both
genders combined.
The dosimetry applied here was rather crude (without
attenuation and scatter correction). However, the goal of
this study was primarily to compare the biodistributions
and biokinetics and the tumour-targeting capacity of
NOCATE in comparison with OCTREO. Most patients did
Table 3 Measured effective half-lives of OCTREO and NOCATE in the whole body, tissues and blood obtained by fitting the tissue results to
biexponential functions (giving α and β half lives) or single exponential functions (for spleen and kidneys)
Organ Effective half-life (h)a Fraction/organ (%) Residence time (h) (Ãs/Ao)
OCTREO NOCATE OCTREO NOCATE OCTREO (our results) OCTREO (ICRP data) NOCATE
Whole body α 2.5±0.6 3.8±1.1 67.7±6.3 34.2±3.3 18.8±3.6 – 41.3±2.1
Whole body β 35.9±5.9 42.8±1.6 32.3±4.2 65.8±2.2
Lung α 3.35±0.3 3.3±1.8 3.3±1.1 1.7±0.3 0.7±0.2 – 1.4±0.2
Lung β 43.6±12.4 41.3±3.7 0.9±0.2 2.2±0.2
Kidneys 29.9±7.5 46.0±10.9 3.8±1.0 3.9±1.1 1.6±0.5 2.8 2.4±0.7
Liver α 3.7±1.3 4.6±2.1 2.6±0.6 4.4±1.3 2.4±0.5 2.6 5.7±1.1
Liver β 59.8±8.1 49.2±7.1 2.8±0.4 7.7±1.0
Spleen 43.8±10.7 40.8±5.7 3.8±1.4 8.2±2.8 2.4±1.2 2.3 4.8±1.9
Remainder of bodyb 10.7±6.4 6.9 26.1±6.2
Blood α 0.3±0.04 0.15±0.1 77.5±4.3 86.3±2.8 2.0±0.4 – 3.7±0.4
Blood β 6.2±0.9 18.5±1.5 22.5±2.4 13.7±0.5
Red marrowc 0.2±0.1 – 0.3±0.1
Bladderd 0.8±0.3 1.7 0.6±0.1
a Results for the whole body, lungs, liver and blood were obtained by fitting all patient results combined to biexponential functions and are shown as
estimated effective α and β half-lives with their respective fractions/organ ± the standard errors (uncertainty) propagated finally into the residence
time; results for the kidneys and spleen were obtained by fitting single exponential functions to the patients individually and are shown as means ±
SD for the effective half-lives, the fractions per organ and the residence times.
b Remainder residence time represents the WB residence time with the residence times of all the other organs and tissues analysed subtracted.
c Red marrow residence time was extrapolated from blood residence time according to the method of Wessels et al. [7] using a blood to marrow
residence time ratio of 0.091.
d Bladder residence time was obtained using the bladder model with a filtration fraction of 1. The α and β biological WB half-lives with their
respective fractions of OCTREO and NOCATE and a bladder voiding interval of 2 h were sequentially introduced into the bladder model and the α
and β residence times summed.
Table 4 Tissue radiation doses
(in micrograys per megabec-
querel). For kidneys and spleen
the values are means ± SD; for
all other organs and tissues for
which biexponential functions
were fitted the values are mean ±
standard error propagated from
the residence times given in
Table 3 The published ICRP data
[9] are also shown)
Organ OCTREO NOCATE NOCATE/OCTREO ratio
ICRP 106 Our results Our results
Lung 23 46±13 99±14 2.2
Kidneys 410 252±79 404±117 1.6
Liver 100 97±20 226±43 2.3
Spleen 570 576±288 1150±455 2.0
Bladder 200 110±41 115±19 1.0
Red marrow 22 27±14 58±19 2.1
Remainder of body 24 29±17 64±15 2.2
Effective dose (μSv/MBq) 54 52 105 2.0
Effective dose equivalent
(μSv/MBq)
87 169 1.9
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not have a CT scan and none had a SPECT/CT scan, al-
though some had a SPECT scan. Independent of the dosim-
etry method used, the comparison of NOCATE and
OCTREO, obtained under identical conditions and under
the same assumptions, remains valid, in our opinion.
Another drawback of this initial study of NOCATE in
comparison with OCTREO is that data collection in these
patients did not include measurement of faecal and urinary
excretion of 111In, and gastrointestinal activity was not
determined since no SPECT/CT data were available.
Retrospectively, considering the much higher uptake of
NOCATE in the liver and spleen than of OCTREO, it would
have been interesting to compare the NOCATE and
OCTREO data by pharmacokinetic compartmental model-
ling. However, the entire protocol was quite demanding for
these patients who underwent multiple scans and blood
drawing. We therefore decided not to request urine and
faeces collection, nor to perform SPECT/CT.
In the absence of measured data, we assumed for dosim-
etry purposes that the activity of NOCATE was also mainly
eliminated via the kidneys, as is observed for OCTREO
according to the ICRP. Indeed, as measured and modelled,
faecal activity excretion on OCTREO scanning was rather
low, representing only between 0.5 and 2 % of injected
activity [10].
The biodistribution of NOCATE had been studied in
male Lewis rats at 7 weeks of age [5]. While the
NOCATE results in rats adequately predicted a long half-
life in tissues including the kidneys, liver and spleen, the
organ uptakes in %ID/g appear rather low in these animals
weighing about 200 g compared with the human data
reported here. The markedly higher effective dose of
NOCATE than of OCTREO as observed here was thus not
predicted from the animal studies.
A similar compound, DOTANOC labelled with 68Ga, has
been studied in humans [11]. Due to methodological differ-
ences (single photon WB scans versus PET), the results are
not directly comparable. However, in that study the activity
of DOTANOC seen in the liver and spleen was about half
that of NOCATE in this study.
The observed differences between NOCATE and
OCTREO cannot be explained conclusively. Different fac-
tors could theoretically explain our observations. The higher
affinity of NOCATE than of OCTREO to different receptor
subtypes could be responsible for a longer retention of
receptor-bound NOCATE. However, the high uptake of
NOCATE in normal liver and spleen probably cannot be
explained in terms of affinity. In fact, while the uptake of
NOCATE in normal liver is roughly double that of
OCTREO, the differences between heavily metastatic livers
and normal livers was very similar for both NOCATE and
OCTREO at all scan times. These findings could suggest
that the high uptake of NOCATE in normal liver and spleen
is nonspecific. Another hypothesis suggests that the longer
β half-life of NOCATE in blood could be due to binding to
globular blood components. This hypothesis can be ruled
out by experimental separation of globular blood compo-
nents from plasma and separate radioactivity counting that
showed that only a minor fraction of NOCATE was bound
to globular blood components.
Conclusion
This comparative study of NOCATE andOCTREO, both radio-
labelled with 111In, showed a higher retention of NOCATE in all
normal organs tested. The blood β half-life of NOCATE was
also longer than that of OCTREO. The absorbed dose of
NOCATE was roughly twice that of OCTREO.
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